Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib

PURPOSE: HER2 (or ERBB2) aberrations, including both amplification and mutations, have been classified as oncogenic drivers that contribute to 2% to 6% of lung adenocarcinomas. HER2 amplification is also an important mechanism for acquired resistance to EGFR tyrosine kinase inhibitors (TKI). However...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Liu, Shengwu, Li, Shuai, Hai, Josephine, Wang, Xiaoen, Chen, Ting, Quinn, Max M., Gao, Peng, Zhang, Yanxi, Ji, Hongbin, Cross, Darren A.E., Wong, Kwok-Kin
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6434713/
https://ncbi.nlm.nih.gov/pubmed/29298799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1875
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky